The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22

被引:96
|
作者
Chow, Edward [1 ]
Hird, Amanda [1 ]
Velikova, Galina [2 ]
Johnson, Colin [3 ]
Dewolf, Linda [4 ]
Bezjak, Andrea [5 ]
Wu, Jackson [6 ]
Shafiq, Jesmin [7 ]
Sezer, Orhan [8 ]
Kardamakis, Dimitrios [9 ]
van der Linden, Yvette [10 ]
Ma, Brigette [11 ]
Castro, Monica [12 ]
Foro Arnalot, Palmira [13 ]
Ahmedzai, Sam [14 ]
Clemons, Mark [5 ]
Hoskin, Peter [15 ]
Yee, Albert [1 ]
Brundaye, Michael [16 ]
Bottomley, Andrew [4 ]
机构
[1] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[2] Univ Leeds, St James Univ Hosp, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[3] Southampton Gen Hosp, Univ Surg Unit, Southampton, Hants, England
[4] European Org Res Treatment Canc, Brussels, Belgium
[5] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada
[6] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[7] Liverpool Hosp, Liverpool, NSW, Australia
[8] Univ Med Berlin, Charite, Berlin, Germany
[9] Univ Patras, Sch Med, GR-26110 Patras, Greece
[10] Radiotherapeut Inst Friesland, Leeuwarden, Netherlands
[11] Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China
[12] Univ Buenos Aires, Inst Oncol Angel H Roffo, RA-1053 Buenos Aires, DF, Argentina
[13] Hosp Esperanza, Barcelona, Spain
[14] St Lukes Hosp, Sheffield, S Yorkshire, England
[15] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England
[16] Kingston Reg Canc Ctr, Kingston, ON, Canada
关键词
Bone metastases; Health-related quality of life; Questionnaire; Cancer; Pain symptoms; EORTC; SUPPORTIVE PAMIDRONATE TREATMENT; BREAST-CANCER; PROSTATE-CANCER; CONTROLLED-TRIAL; ZOLEDRONIC ACID; ORAL CLODRONATE; PAIN; IBANDRONATE; PLACEBO; CARCINOMA;
D O I
10.1016/j.ejca.2008.11.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The aim of this study was to develop a bone metastases module to supplement the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30) or the EORTC QLQ-C15-PAL for patients with bone metastases. Methods Phases 1-2 of module development were conducted in Canada, Australia and Germany according to EORTC QOL group guidelines. Phase 3 was conducted in nine countries in seven languages. Results: Sixty-one health-related quality of life (HRQOL) issues were generated from health care professionals (n = 152) and patients (n = 413). This resulted in a 22-item provisional module. Further testing in 170 patients from nine countries resulted in the EORTC QLQ-BM22 module, containing 22 items, conceptualised into both symptom scales, with five painful sites and three pain characteristics, and also functional scales, with eight functional interference and six psychosocial aspects. Conclusion: This study provides a provisional comprehensive HRQOL measurement tool for future trials, which will continue to undergo further validation. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1146 / 1152
页数:7
相关论文
共 50 条
  • [41] The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation of English version in Singapore
    Luo, N
    Fones, CSL
    Lim, SE
    Xie, F
    Thumboo, J
    Li, SC
    QUALITY OF LIFE RESEARCH, 2005, 14 (04) : 1181 - 1186
  • [42] Psychometric properties of the Spanish version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
    Caterina Calderon
    Pere J. Ferrando
    Urbano Lorenzo-Seva
    Estrella Ferreira
    Eun Mi Lee
    Marta Oporto-Alonso
    Berta M. Obispo-Portero
    Luka Mihic-Góngora
    Adan Rodríguez-González
    Paula Jiménez-Fonseca
    Quality of Life Research, 2022, 31 : 1859 - 1869
  • [43] Use of the European Organisation for research and treatment of cancer quality of life Multiple Myeloma questionnaire (EORTC QLQ-MY20): a review of the literature 25 years after development
    Tinsley, Katie
    Cocks, Kim
    Greenwood, Mike
    Wells, Jane
    Bristogiannis, Sotirios
    Kyriakou, Charalampia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S106 - S107
  • [44] The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation of English version in Singapore
    N. Luo
    C. S. L. Fones
    S. E. Lim
    F. Xie
    J. Thumboo
    S. C. Li
    Quality of Life Research, 2005, 14 : 1181 - 1186
  • [45] The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation Study of the Thai Version
    Chatchawan Silpakit
    Suwanee Sirilerttrakul
    Manmana Jirajarus
    Thitiya Sirisinha
    Ekaphop Sirachainan
    Vorachai Ratanatharathorn
    Quality of Life Research, 2006, 15 : 167 - 172
  • [46] European Organisation for Research and Treatment of Cancer (EORTC)
    不详
    BREAST CARE, 2006, 1 (03) : 202 - 202
  • [47] Current Developments in Measuring Quality of Life with Instruments of the European Organisation for Research and Treatment of Cancer (EORTC)
    Singer, S.
    Hofmeister, D.
    Spiegel, K.
    Boehm, A.
    LARYNGO-RHINO-OTOLOGIE, 2011, 90 (10) : 591 - 594
  • [48] Validity and reliability of lung cancer quality of life Questionnaire from European Organization for Research and Treatment of Cancer (EORTC QLQ-LC13) in Iran
    Motlagh, Karbasi M.
    Enjedani, E.
    Zamanian, H.
    Fathollahbeigy, F.
    Kiayee, N.
    Meybodi, Aghaie F.
    Beheshtee, M.
    HEALTHMED, 2012, 6 (06): : 2121 - 2124
  • [49] The European organization for research and treatment of cancer quality of life core questionnaire (EORTC QLQ-C30): Validation of English version in Singapore
    Xie, F
    Luo, N
    Li, SC
    VALUE IN HEALTH, 2004, 7 (03) : 252 - 252
  • [50] The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the Iranian version
    Montazeri, A
    Harirchi, I
    Vahdani, M
    Khaleghi, F
    Jarvandi, S
    Ebrahimi, M
    Haji-Mahmoodi, M
    SUPPORTIVE CARE IN CANCER, 1999, 7 (06) : 400 - 406